Galderma
2 products
Showing 1 - 2 of 2 products
Galderma – Advancing Dermatology for Every Skin Story
Founded in 1981 as a joint venture between Nestlé and L'Oréal, Galderma has evolved into a leading global dermatology company headquartered in Zug, Switzerland. With a presence in over 100 countries and a workforce of more than 6,500 employees, Galderma is dedicated to advancing dermatology through innovative and science-based solutions.
Product Portfolio
Galderma's diverse product portfolio spans three core areas:
1. Injectable Aesthetics
-
Restylane®: A range of hyaluronic acid-based dermal fillers used for facial wrinkles and volume loss.
-
Sculptra®: A poly-L-lactic acid injectable that stimulates collagen production for long-lasting facial volume restoration.
-
Dysport®: A botulinum toxin type A product used to treat glabellar lines and other aesthetic indications.
2. Dermatological Skincare
-
Cetaphil®: A dermatologist-recommended brand offering gentle skincare products for sensitive skin, including cleansers and moisturizers.
-
Alastin Skincare®: Products designed to enhance aesthetic procedures and support daily skin health.
3. Therapeutic Dermatology
-
Twyneo®: A combination of tretinoin and benzoyl peroxide for the treatment of acne vulgaris.
-
Nemluvio® (nemolizumab): A monoclonal antibody approved for the treatment of prurigo nodularis and atopic dermatitis.
-
Oracea®: An oral therapy for the treatment of inflammatory lesions of rosacea.
Global Presence and Operations
Galderma operates four manufacturing sites and produces over 300 million units annually. The company has conducted more than 770 clinical trials across 30+ countries since 2019 and has received over 160 major regulatory approvals in the same period. Galderma's Global Aesthetic Injector Network (GAIN) has trained over 130,000 healthcare professionals, emphasizing its commitment to education and excellence in dermatology.
Leadership
Dr. Flemming Ørnskov has been serving as the CEO of Galderma since October 2019. With a background in medicine and business, Dr. Ørnskov brings extensive experience from previous leadership roles in global pharmaceutical companies.
